MA26610A1 - Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques - Google Patents

Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques

Info

Publication number
MA26610A1
MA26610A1 MA25473A MA25473A MA26610A1 MA 26610 A1 MA26610 A1 MA 26610A1 MA 25473 A MA25473 A MA 25473A MA 25473 A MA25473 A MA 25473A MA 26610 A1 MA26610 A1 MA 26610A1
Authority
MA
Morocco
Prior art keywords
racemic
isomers
salts
pharmaceutical compositions
therapeutic agents
Prior art date
Application number
MA25473A
Other languages
English (en)
Inventor
Marie Caroon Joan
Patrick Dillon Michael
New Harris Ralph Iii
Jeou Jen Lin Clara
Maag Hans
Bruce Repke David
Douglas Clark Robin
Surendra Hegde Sharathchandra
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA26610A1 publication Critical patent/MA26610A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/08—Mydriatics or cycloplegics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MA25473A 1998-02-27 1999-02-25 Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques MA26610A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7611398P 1998-02-27 1998-02-27
US10909798P 1998-11-19 1998-11-19

Publications (1)

Publication Number Publication Date
MA26610A1 true MA26610A1 (fr) 2004-12-20

Family

ID=26757679

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25473A MA26610A1 (fr) 1998-02-27 1999-02-25 Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques

Country Status (27)

Country Link
US (1) US6319920B1 (fr)
EP (1) EP1058680B1 (fr)
JP (1) JP3523198B2 (fr)
KR (1) KR100384906B1 (fr)
CN (1) CN1143848C (fr)
AR (1) AR015523A1 (fr)
AT (1) ATE400554T1 (fr)
AU (1) AU753255B2 (fr)
BR (1) BR9909253A (fr)
CA (1) CA2321198C (fr)
CO (1) CO4990939A1 (fr)
DE (1) DE69939053D1 (fr)
ES (1) ES2310032T3 (fr)
HK (1) HK1036623A1 (fr)
HR (1) HRP20000544A2 (fr)
HU (1) HUP0100760A3 (fr)
IL (1) IL137936A0 (fr)
MA (1) MA26610A1 (fr)
MY (1) MY133445A (fr)
NO (1) NO317106B1 (fr)
NZ (1) NZ506317A (fr)
PE (1) PE20000325A1 (fr)
PL (1) PL194037B1 (fr)
RU (1) RU2220138C2 (fr)
TR (1) TR200002481T2 (fr)
WO (1) WO1999043657A1 (fr)
YU (1) YU53100A (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012150A4 (fr) * 1997-05-19 2002-05-29 Sugen Inc Composes d'heteroarylcarboxamide actifs contre les etats pathologiques lies aux proteine tyrosine kinases
YU88902A (sh) 2000-05-25 2006-01-16 F. Hoffmann-La Roche Ag. Supstituisani 1-aminoalkil laktami i njihova primena kao antagonista muskarinskih receptora
YU89002A (sh) 2000-05-25 2006-01-16 F. Hoffmann-La Roche Ag. Supstituisani 1-aminoalkil-laktami i njihova primena kao antagonista za muskarinske receptore
CA2468691C (fr) * 2001-12-03 2011-03-08 F. Hoffmann-La Roche Ag Utilisation de derives de 4-piperidinyl alkylamine en tant qu'antagonistes des recepteurs muscariniques
EP1453806B1 (fr) * 2001-12-03 2007-12-19 F. Hoffmann-La Roche Ag Derives d'aminotetraline utilises comme antagonistes des recepteurs muscariniques
EP1552825A4 (fr) * 2002-06-07 2009-11-25 Astellas Pharma Inc Agent therapeutique pour le traitement de l'hyperactivite vesicale
CN1668585A (zh) 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TWI295669B (en) * 2002-10-30 2008-04-11 Theravance Inc Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
AU2003301184A1 (en) * 2002-12-20 2004-07-22 Dynogen Pharmaceuticals Inc METHODS OF TREATING NON-PAINFUL BLADDER DISORDERS USING Alpha2Delta SUBUNIT CALCIUM CHANNEL MODULATORS
JP2006520799A (ja) * 2003-03-21 2006-09-14 ダイノジェン ファーマシューティカルズ， インコーポレイテッド 平滑筋調節因子およびα２δサブユニットカルシウムチャネル調節因子を用いた、下部尿路障害を処置するための方法
EP1618091A1 (fr) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Derives d'azabicyclo hexane substitues en tant qu'antagonistes de recepteurs muscariniques
AU2004228452A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
EP1644356A1 (fr) * 2003-07-11 2006-04-12 Theravance, Inc. Composes de 4-amino-1-benzylpiperidine substitues
US7214439B2 (en) * 2003-12-19 2007-05-08 Millennium Cell, Inc. Triborohydride salts as hydrogen storage materials and preparation thereof
CN101663270B (zh) 2007-04-24 2013-07-17 施万制药 可用作蕈毒碱受体拮抗剂的季铵化合物
DE102007020492A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
EP3170807B1 (fr) * 2015-11-23 2019-12-11 Frau Pharma S.r.l. Nouveau procédé de synthèse de la fenfluramine
SI25272A (sl) 2016-09-23 2018-03-30 Univerza V Ljubljani Disubstituirani azetidini, pirolidini, piperidini in azepani kot zaviralci monoamin oksidaze B za zdravljenje nevrodegenerativnih bolezni
CN112824378A (zh) * 2019-11-20 2021-05-21 珠海润都制药股份有限公司 一种盐酸坦索罗辛的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361791B1 (fr) 1988-09-26 1995-11-08 Smithkline Beecham Farmaceutici S.p.A. Composés azacycliques, utiles commes médicaments
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
FR2681320B1 (fr) 1991-09-12 1994-01-14 Synthelabo Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
FR2681325B1 (fr) 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
JP3064425B2 (ja) 1995-09-15 2000-07-12 ノイロサーチ アクティーゼルスカブ カルシウムチャンネル・ブロッカーとしてのピペリジン化合物
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate

Also Published As

Publication number Publication date
CN1295563A (zh) 2001-05-16
IL137936A0 (en) 2001-10-31
JP2002504543A (ja) 2002-02-12
DE69939053D1 (de) 2008-08-21
WO1999043657A1 (fr) 1999-09-02
AU753255B2 (en) 2002-10-10
ES2310032T3 (es) 2008-12-16
TR200002481T2 (tr) 2000-11-21
CA2321198C (fr) 2009-11-17
HRP20000544A2 (en) 2001-02-28
AU2835399A (en) 1999-09-15
CO4990939A1 (es) 2000-12-26
NO20004261L (no) 2000-08-25
HUP0100760A2 (hu) 2001-08-28
US6319920B1 (en) 2001-11-20
MY133445A (en) 2007-11-30
EP1058680A1 (fr) 2000-12-13
RU2220138C2 (ru) 2003-12-27
NZ506317A (en) 2003-08-29
HK1036623A1 (en) 2002-01-11
BR9909253A (pt) 2000-11-28
PL194037B1 (pl) 2007-04-30
ATE400554T1 (de) 2008-07-15
CA2321198A1 (fr) 1999-09-02
AR015523A1 (es) 2001-05-02
EP1058680B1 (fr) 2008-07-09
CN1143848C (zh) 2004-03-31
PE20000325A1 (es) 2000-05-08
PL342692A1 (en) 2001-07-02
KR100384906B1 (ko) 2003-05-23
KR20010041321A (ko) 2001-05-15
NO20004261D0 (no) 2000-08-25
JP3523198B2 (ja) 2004-04-26
HUP0100760A3 (en) 2002-12-28
NO317106B1 (no) 2004-08-09
YU53100A (sh) 2003-04-30

Similar Documents

Publication Publication Date Title
MA26610A1 (fr) Antagonistes des recepteurs muscariniques et leurs sels, isomeres et melanges racemiques ou non racemiques, compositions pharmaceutiques les contenant, et procede pour les utiliser en tant qu'agents therapeutiques
MA26415A1 (fr) Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant
FR2780728B1 (fr) Sel de paroxetine nouveau, procede pour sa preparation et compositions pharmaceutiques le contenant
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26526A1 (fr) Derives d'indole inhibiteurs de cyclo-oxygenase, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2789079B3 (fr) Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2740136B1 (fr) Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
MA26536A1 (fr) Association de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation.
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26571A1 (fr) Derives d'acide hydroxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26653A1 (fr) Pyrrolo [2,3- d] pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26432A1 (fr) Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26516A1 (fr) Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
FR2785902B1 (fr) 4-aroylpiperidines antagonistes du recepteur du ccr-3, compositions pharmaceutiques les contenant, procede pour les utiliser et les preparer
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98083A1 (fr) Derives de 6-0 methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99198A1 (fr) PYRAZOLOPYRIMIDINONES NOUVELLES INHIBITRICES DE PDE-5 GMPc, PROCEDE POUR LEUR PREPARATION ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
TNSN98151A1 (fr) Derives de 2 - (4 - aryl - ou heteroaryl - piperazine - 1 - ylmethyl) -1 h - indole.
FR2687676B1 (fr) Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant.
TNSN99255A1 (fr) Derives de piperidine et de morpholine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant